Welcome to BOPA
Latest news from BOPA
Safer Prescribing of Cytotoxic Agents - Academy of Medical Royal Colleges Report April 2015
The Academy of Medical Royal Colleges has published a report entitled: Achieving safer prescription of cytotoxic agents: Academy recommendations
Simon Purcell, BOPA Executive Committee member was involved in the preparation of this guidance. Link - http://www.aomrc.org.uk
Prescribing of cytotoxic drugs, immunosuppressant agents and drugs with a narrow therapeutic index by inadequately trained doctors is a longstanding problem. Current systems lack appropriate safeguards and an ongoing and predictable risk to patient safety remains. Recommendations for actions required to address these safety concerns include:Read More
For details on the forthcoming:
The Introduction to Oncology Course is now fully booked. If you are interested in being waitlisted for this course, please contact Anthony O'Rawe on 01628 897 940.
BOPA Study Days
BOPA are hosting 4 study days with Dr Elaine Vickers on the following topics:
The Science of Targeted Cancer Treatments: 19th & 22nd May 2015
Targeted Treatments for Haematological: 8th & 9th September 2015
Click here for more information
First Early Access to Medicines (EAMS) Scientific Opinion issued by MHRA
The MHRA has issued its first Early Access to Medicines (EAMS) scientific opinion.
It is for a product called pembrolizumab, used to treat advanced melanoma which has spread or cannot be removed by surgery and has progressed after other treatments. The MHRA assessment team considered that pembrolizumab had been shown to slow the progression of cancer in a condition where other treatments currently have poor results.
Details of the scientific opinion (https://www.gov.uk/government/publications/early-access-to-medicines-scheme-eams-scientific-opinion-pembrolizumab-mk-3475) can be found on the MHRA website, as well as background information on EAMS (https://www.gov.uk/apply-for-the-early-access-to-medicines-scheme-eams).